teaser
A meta-analysis comparing enoxaparin with unfractionated heparin (UFH) in all acute coronary syndromes (ACS) concludes that overall, enoxaparin gives better outcomes: a higher incidence of major bleeding is outweighed by fewer serious cardiovascular events.
↓Article continues below this sponsored advert↓
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
↑Advertisement↑
The authors note that while anti-thrombin therapy is an established central treatment in ACS, it is still unclear which drug gives best results overall. There is considerable trial data available for the low-molecular-weight heparin enoxaparin, and the aim of this analysis was to determine whether this is associated with a better balance of risk and safety than UFH.
The authors carried out a literature search for controlled trials comparing enoxaparin with UFH in patients with ACS
